Abstract
Yuheng Pang, Yuefeng Shang, Zou Xiaolong
Abstract
Authors
Institutions
Provenance
crossref
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Recent Advances in Therapeutic Strategies for Triple‐Negative Breast Cancer
10.1186/s13045-022-01341-0 · 2022
Treatment Landscape of Triple‐Negative Breast Cancer ‐ Expanded Options, Evolving Needs
10.1038/s41571-021-00565-2 · 2022
Triple‐Negative Breast Cancer Therapeutic Resistance: Where Is the Achilles' Heel?
10.1016/j.canlet.2020.10.016 · 2021
Tumor Microenvironment: Challenges and Opportunities in Targeting Metastasis of Triple Negative Breast Cancer
10.1016/j.phrs.2020.104683 · 2020
Therapeutic Targets in Triple Negative Breast Cancer Where Are We Now?
10.2174/157489211795328521 · 2011
An Insight Into Molecular Targets of Breast Cancer Brain Metastasis
10.3390/ijms231911687 · 2022
Crosstalk Between Cancer‐Associated Fibroblasts and Immune Cells in the Tumor Microenvironment: New Findings and Future Perspectives
10.1186/s12943-021-01428-1 · 2021
Stromal Characteristics and Impact on New Therapies for Metastatic Triple‐Negative Breast Cancer
10.3390/cancers14051238 · 2022
Epithelial‐Mesenchymal Transition and Tumor‐Associated Macrophage Axis in Metastatic Breast Cancer: Converging Mechanisms and Therapeutic Perspectives
Confidence 100%
ror
Confidence 99%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1016/j.lfs.2025.124084 · 2026
DNA Methylation and Immune Evasion in Triple‐Negative Breast Cancer: Challenges and Therapeutic Opportunities
10.3389/fonc.2025.1534055 · 2025
The lncRNA AFAP1‐AS1 Is Upregulated in Metastatic Triple‐Negative Breast Tumors and Controls Hypoxia‐Activated Vasculogenic Mimicry and Angiogenesis
10.1186/s12885-024-13019-6 · 2024
Metabolic Reprogramming in Triple‐Negative Breast Cancer
10.20892/j.issn.2095-3941.2019.0210 · 2020
Distinct Tumor Architectures and Microenvironments for the Initiation of Breast Cancer Metastasis in the Brain
10.1016/j.ccell.2024.08.015 · 2024
The Technological Landscape and Applications of Single‐Cell Multi‐Omics
10.1038/s41580-023-00615-w · 2023
Single‐Cell Transcriptomic Analysis Reveals the Landscape of Epithelial‐Mesenchymal Transition Molecular Heterogeneity in Esophageal Squamous Cell Carcinoma
10.1016/j.canlet.2024.216723 · 2024
Metabolomics and EMT Markers of Breast Cancer: A Crosstalk and Future Perspective
10.3390/pathophysiology29020017 · 2022
Immune Monitoring Using Mass Cytometry and Related High‐Dimensional Imaging Approaches
10.1038/s41584-019-0338-z · 2020
The COSMIC Cancer Gene Census: Describing Genetic Dysfunction Across All Human Cancers
10.1038/s41568-018-0060-1 · 2018
Single‐Cell Analysis by Mass Cytometry Reveals Metabolic States of Early‐Activated CD8(+) T Cells During the Primary Immune Response
10.1016/j.immuni.2021.02.018 · 2021
Spatial Predictors of Immunotherapy Response in Triple‐Negative Breast Cancer
10.1038/s41586-023-06498-3 · 2023
Breast Tumor Microenvironment Structures Are Associated With Genomic Features and Clinical Outcome
10.1038/s41588-022-01041-y · 2022
UDP‐Glucose Dehydrogenase Expression Is Upregulated Following EMT and Differentially Affects Intracellular Glycerophosphocholine and Acetylaspartate Levels in Breast Mesenchymal Cell Lines
10.1002/1878-0261.13172 · 2022
Nucleotide Metabolism: A Pan‐Cancer Metabolic Dependency
10.1038/s41568-023-00557-7 · 2023
Distinct Metabolic Dependency on BCAA Defines Cancer Stemness and Malignancy in Human Triple‐Negative Breast Cancer
10.1016/j.celrep.2026.117630 · 2026
Amino Acid Metabolism in Breast Cancer: Pathogenic Drivers and Therapeutic Opportunities
10.1093/procel/pwaf011 · 2025
The Taurine‐Slc6a6 Axis Promotes Breast Cancer Progression by Alleviating Oxidative Stress and Accelerating Cell Cycle Progression
10.3390/cells15020207 · 2026
Modeling the Role of Cancer‐Associated Fibroblasts in Tumor Cell Invasion
10.3390/cancers14040962 · 2022
Multi‐OMICS Approaches in Cancer Biology: New Era in Cancer Therapy
10.1016/j.bbadis.2024.167120 · 2024
The Epithelial‐Mesenchymal Transition at the Crossroads Between Metabolism and Tumor Progression
10.3390/ijms23020800 · 2022
The Molecular Mechanisms and Therapeutic Strategies of EMT in Tumor Progression and Metastasis
10.1186/s13045-022-01347-8 · 2022
Emerging Mechanisms by Which EMT Programs Control Stemness
10.1016/j.trecan.2020.03.011 · 2020
Wnt/Beta‐Catenin Mediated Signaling Pathways in Cancer: Recent Advances, and Applications in Cancer Therapy
10.1186/s12943-025-02363-1 · 2025
The Role of Tumor Epithelial‐Mesenchymal Transition and Macrophage Crosstalk in Cancer Progression
10.1007/s11914-023-00780-z · 2023
EMT, MET, Plasticity, and Tumor Metastasis
10.1016/j.tcb.2020.07.003 · 2020
Metabolic Reprogramming and Cancer Progression
10.1126/science.aaw5473 · 2020
Branched‐Chain Amino Acid and Cancer: Metabolism, Immune Microenvironment and Therapeutic Targets
10.1186/s12967-025-06664-3 · 2025
Cancer Metabolism: Looking Forward
10.1038/s41568-021-00378-6 · 2021
Focus on the Glycerophosphocholine Pathway in Choline Phospholipid Metabolism of Cancer
10.1002/nbm.4112 · 2019
Metabolic Reprogramming of Cancer‐Associated Fibroblasts and Its Effect on Cancer Cell Reprogramming
10.7150/thno.62378 · 2021
Microenvironmental Regulation of Tumor Progression and Metastasis
10.1038/nm.3394 · 2013
Single‐Cell Multi‐Omics in Cancer Immunotherapy: From Tumor Heterogeneity to Personalized Precision Treatment
10.1186/s12943-025-02426-3 · doi-reference
Targeting Metastatic Cancer
10.1038/s41591-020-01195-4 · doi-reference
Clinical and Therapeutic Relevance of Cancer‐Associated Fibroblasts
10.1038/s41571-021-00546-5 · doi-reference
Spatial Multiomics of the Breast Tumour Microenvironment: State of the Field, Advancements and Clinical Implementation Promises
10.1016/j.critrevonc.2025.105082 · doi-reference
TGFbeta Drives Immune Evasion in Genetically Reconstituted Colon Cancer Metastasis
10.1038/nature25492 · doi-reference